IO Biotech

IO Biotech Diluted EPS

Delisted·Sep 22, 2026

The Diluted Earnings per Share of IO Biotech (IOBT) as of Nov 20, 2026 is -1.45 USD. In the previous year, Diluted Earnings per Share was -1.31 USD — a change of 10.93% (lower).

Diluted EPS

-1.45USD

YoY

10.93%

Last updated:

Diluted Earnings per Share of IO Biotech is 2024 -1.45 USD. Diluted Earnings per Share of IO Biotech was 2023 -1.31 USD. It decreases by 10.93% lower compared to the previous year.

The IO Biotech Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2019
-0.16 USD
Jan 1, 2020
-1.04 USD
Jan 1, 2021
-2.64 USD
Jan 1, 2022
-2.48 USD
Jan 1, 2023
-1.31 USD
Jan 1, 2024
-1.45 USD
The IO Biotech Diluted EPS history
YEARDiluted EPSYoY
-1.45USD+10.93%
-1.31USD-47.31%
-2.48USD-6.01%
-2.64USD+153.02%
-1.04USD+549.40%
-0.16USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

Diluted Earnings per Share of IO Biotech is -1.45 USD in 2024.

Diluted Earnings per Share of IO Biotech changed from -1.31 USD to -1.45 USD, representing a 10.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share IO Biotech since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — IO Biotech

All Key Metrics — IO Biotech